Pemetrexed in heavily pretreated non-small-cell lung cancer patients: Case report and review of the literature

Future Oncology

Volumn 6, Issue 12, 2010, Pages 1937-1940

  Tartarone, Alfredo ^a  

^a REFERRAL CANCER CENTER OF BASILICATA   (Italy)

Author keywords

clinical decision making; nonsquamous non small cell lung cancer; pemetrexed; salvage chemotherapy; thymidylate synthase

Indexed keywords

CISPLATIN; CISPLATIN PLUS VINORELBINE; CYANOCOBALAMIN; DOCETAXEL; ERLOTINIB; FOLIC ACID; GEMCITABINE; NAVELBINE; PEMETREXED; UNCLASSIFIED DRUG;

ADULT; BONE METASTASIS; BRAIN METASTASIS; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; LUNG ADENOCARCINOMA; MALE; NAUSEA AND VOMITING; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; FATAL OUTCOME; GLUTAMATES; GUANINE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PALLIATIVE CARE;

EID: 78650424533     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.146     Document Type: Review

References (24)

1. Adjei AA: Pemetrexed (Alimta), a novel multitargeted antineoplastic agent. Clin. Cancer Res. (Suppl.) 10, 4276S-4280S (2004).
2. Manegold C, Gatzemeier U, von Pawel J et al.: Front-line treatment of advanced non small cell lung cancer with MTA (LY231514, pemetrexed disodium, Alimta) and cisplatin: a multicenter Phase II trial. Ann. Oncol. 11, 435-440 (2000).
3. Shepherd FA, Dancey J, Arnold A et al.: Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced non small cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Cancer 92, 595-600 (2001).
4. Vogelzang NJ, Rusthove JJ, Symanowsky J et al.: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21, 2636-2644 (2003).
5. Scagliotti G, Hanna N, Fossella F et al.: The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 14, 253-263 (2009).
6. Azzoli CG, Baker S Jr, Termin S et al.: American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non small cell lung cancer. J. Clin. Oncol. 27, 6251-6266 (2009).
7. De Marinis F, Grossi F: Clinical evidence for second and third line treatment options in advanced non small cell lung cancer. Oncologist 13(Suppl. 1), 14-20 (2008).
8. Matsuyama R, Reddy S, Smith T: Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. J. Clin. Oncol. 24, 3490-3496 (2006).
9. Massarelli E, Andre F, Liu DD et al.: A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non small cell lung cancer. Lung Cancer 39, 55-61 (2003).
10. Scagliotti GV, Parikh P, von Pawel J et al.: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non small cell lung cancer. J. Clin. Oncol. 26, 3543-3355 (2008).
11. Hanna N, Shepherd FA, Fossella et al.: Randomized Phase III trial of pemetrexed versus docetaxel in patients with non small cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 22, 1589-1597 (2004).
12. Ciuleanu T, Brodowicz T, Zielinski C et al.: Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non small cell lung cancer: a randomised, double-bind, Phase III study. Lancet 374(9699), 1432-1440 (2009).
13. Scagliotti GV, Park K, Patil S et al.: Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaive patients with advanced non small cell cell lung cancer: a risk-benefit analysis of a large Phase III study. Eur. J. Cancer 45(13), 2298-2303 (2009).
14. Thatcher N, Chang A, Parikh P et al.: Gefitinib plus best supportive care in previously treated patients with refractory advanced non small cell lung cancer: results from randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366, 1527-1537 (2005).
15. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al.: Erlotinib in previously treated non small cell lung cancer. N. Engl. J. Med. 353, 123-132 (2005).
16. Pujol JL, Paul S, Chouaki N et al.: Survival without common toxicity criteria grade 3-4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non small cell lung cancer (NSCLC): a risk-benefit analysis. J. Thorac. Oncol. 2, 397-401 (2007).
17. Peterson P, Park K, Fossella et al.: Is pemetrexed more more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a Phase III trial of pemetrexed versus docetaxel in previously treated patients with advanced non small cell lung cancer. Presented at: 12th World Conference on Lung Cancer. Seoul, South Korea, 2-6 September 2007.
18. Ceppi P, Volante M, Saviozzi S et al.: Squamous cell carcinoma of the lung comparred with other histiotypes shows higher mRNA and protein levels for thymidylate synthase. Cancer 107, 1589-1596 (2006).
19. Felip E, Rosell R: Pemetrexed as second-line therapy for advanced non small cell lung cancer (NSCLC). Ther. Clin. Risk Manag. 4(3), 579-585 (2008).
20. Sun JM, Lee KW, Kim JH et al.: Efficacy and toxicity of pemetrexed as a third-line treatment for non small cell lung cancer. Jpn J. Clin. Oncol. 39, 27-32 (2009).
21. Chang MH, Ahn JS, Lee J et al.: The efficacy of pemetrexed as a third or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non small cell lung cancer. Lung Cancer 69(3), 323-329 (2010).
22. Kim HS, Lee GW, Kim HY et al.: A Phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non small cell lung cancer. Lung Cancer 70(1), 71-76 (2010).
23. Manson GV, Ma PC: Response to pemetrexed chemotherapy in lung adenocarcinoma-bronchiolalveolar carcinoma insensitive to erlotinib. Clin. Lung Cancer 11, 57-60 (2010).
24. US FDA homepage www.fda.gov